About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2018
2017
2016
2015
2014
2013
2012
Dec 31, 2013 7:00 AM EST
OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker
Dec 30, 2013 1:00 AM EST
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
Dec 23, 2013 7:00 AM EST
Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis
Dec 19, 2013 7:00 AM EST
Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
Dec 11, 2013 7:00 AM EST
Can-Fite CEO Issues Letter to Shareholders
Dec 5, 2013 7:00 AM EST
Can-Fite Anticipates Results from Two Clinical Trials
Dec 2, 2013 7:00 AM EST
Can-Fite CEO to Ring Opening Bell at New York Stock Exchange
Nov 20, 2013 7:00 AM EST
Can-Fite BioPharma Generates Partnership Interest at Therapeutic Area Partnerships Conference in Boston
Nov 15, 2013 7:00 AM EST
Can-Fite BioPharma Announces Approval of ADR Listing on NYSE MKT
Nov 11, 2013 7:00 AM EST
Can-Fite BioPharma to Conduct U.S. Road Show on November 18 - 21, 2013
1
2
3
Next >>
Show All
